Strengzen and Caixa Innvierte Start, new funds March 2016

, ,
Integral service around a transaction
BY : Diego GutiérrezMarch Thu, 2016
Avet Ventures has just launched its first fund to invest in innovative companies. In addition, La Caixa and the CDTI want to help boost the biotechnology sector in our country and have already made the first investment of its Caixa Innvierte Start fund, which will invest in early stage companies in the field of health. 


Avet Ventures launches Strengzen, its first proprietary investment vehicle

Avet Ventures has launched its first own fund, Strengzen Invest, to invest temporarily in innovative companies, not only in dotcoms, but also in more traditional sectors, such as retail and FMCG.

Avet Ventures was established in January 2015 as a management company of closed-end investment entities and started operating, managing the portfolio of investees of the funds FonsInnocat and Highgrowth Innovation, after the closing of the firm. Highgrowth Partners.

Avet is now launching its own venture capital instrument. This fund, despite the firm's initial intentions, will be a small fund. The company has been set up with resources of €1.4M but already has €5M, and its final figure could be between €6M and €10M.

The intention, according to the company's president, is to execute between eight and ten investments with an average amount of between 250,000 euros and 300,000 euros.


La Caixa and the CDTI launch a fund for science start-ups

A month ago we already told you about this fund in one of our posts, but now we know that it has started its activity and has invested in Aelix, a company from the Catalan research centre Hivacat that works on the development of a therapeutic AIDS vaccine.

This fund will invest in early stage biotech companies. Normally these companies have difficulty finding capital in our country, as these companies need a long time to reach the market because they have to comply with regulatory steps that delay the process. Firms like Aelix spend years in research phases, tests on animals and then on human beings before they can have a definitive result that can be marketed.

The investments of this new fund will be between 500,000 and 2 million euros in each operation, through capital contributions, taking minority stakes in the start-ups.

The fund will invest in ten to twenty companies, mostly in the life sciences, per year.

 If you are looking for funding for your startup, contact us. Abra-Invest has a team of experts in alternative financing at your disposal. Call + 34 946424142 or fill in the contact form.

Other posts that may interest you

Caixa Capital Risk invests in Inbiomotion

Divestment of Avet Ventures in the Catalan company Nuroa

New venture capital funds for SMEs: Meridia capital and Closa Gordon

The M&A Professionals

Meet our services



Do you want to be up to date?


Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?